IMPORTANT DEADLINE ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Federal Securities Class Action Lawsuit Has Been Filed Against AirMedia Group, Inc. -- AMCN

20:00 EDT 5 Aug 2015 | Globe Newswire

NEW YORK, Aug. 05, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class of investors, who purchased American Depositary Receipts (ADR’s) of AirMedia Group, Inc. (“AirMedia” or the “Company”) (NASDAQ:AMCN) between April 15, 2015 and June 15, 2015, inclusive (the “Class Period”).  Wolf Haldenstein encourages all shareholders who suffered losses on ADRs purchased within the Class Period to contact us immediately at or (800) 575-0735.

The Complaint alleges that throughout the Class Period, Defendants made false and misleading statements regarding the purported sale of a 5% interest in AirMedia's   advertising   subsidiary,   AirMedia   Group   Co.,   Ltd.   (“AM Advertising”), to Shenzhen Liantronics Co., Ltd., and the valuation of the subsidiary negotiated in the deal.  AirMedia's   press   release announcing the sale stated that the deal “reflected the total valuation of AM Advertising of RMB3 billion,” or $500 million. The complaint further alleges that  defendants made  additional  statements  during  the  Class  Period  claiming  that  RMB3 billion/$500 million was a solid  valuation of the AM Advertising  subsidiary.

As a result of defendants' false and misleading statements during the Class Period, AirMedia ADRs traded at artificially inflated prices, reaching a high price of $7.70 per ADR in intraday trading on June 15, 2015.

On June 15, 2015, the  Company issued a press  release announcing that it  had entered into  a definitive  agreement to  sell  a 75%  equity interest  in  AM Advertising to Beijing Longde Wenchuang Fund Management Co., Ltd. for  RMB2.1 billion/$344.4 million,  significantly  less  than  the  purported  value  the Company had claimed the subsidiary was worth during the Class Period.

As a result of this disclosure, the price of AirMedia ADR’s fell more than 50% over the subsequent days.

If you purchased AirMedia securities during the Class Period, you may, no later than August 24, 2015, request that the Court appoint you lead plaintiff of the proposed class.  A lead plaintiff is a representative party that acts on behalf of all class members in directing the litigation.  Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at, or visit our website at  All e-mail correspondence should make reference to the “AirMedia Investigation.”

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


Wolf Haldenstein Adler Freeman & Herz LLP 
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email:, or
Tel: (800) 575-0735 or (212) 545-4774

More From BioPortfolio on "IMPORTANT DEADLINE ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Federal Securities Class Action Lawsuit Has Been Filed Against AirMedia Group, Inc. -- AMCN"

Quick Search


Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...